The National Health Surveillance Agency (Anvisa) has suspended the commercialization of catheters and infusion pump lines in Brazil. The measure was adopted as part of the agency's health surveillance actions to ensure the safety of products offered to consumers and healthcare professionals.
The suspension represents an important regulatory action in controlling medical devices marketed in Brazil. Catheters and infusion pump lines are critical supplies used in hospital and healthcare settings, being essential for various clinical procedures.
Anvisa's decision reflects the agency's commitment to maintaining regulatory compliance and product quality available in the pharmaceutical and medical device market. These actions are essential to protect the integrity of therapeutic processes and ensure that only products meeting the technical and safety criteria established by regulation can be commercialized.
Healthcare professionals and facilities using these supplies should be aware of Anvisa's guidance and seek regularized alternatives for their operational needs. The agency maintains continuous monitoring of products on the market and may adopt precautionary measures whenever it identifies potential safety risks.
This suspension is part of Anvisa's post-commercialization surveillance scope, which continuously monitors the compliance of medical devices and supplies after their market authorization approval, ensuring they remain safe and effective during use.
